TY - JOUR T1 - Radiotherapy and Tyrosine Kinase Inhibitors in Stage IV Non-small Cell Lung Cancer: Real-life Experience JF - In Vivo JO - In Vivo SP - 159 LP - 164 VL - 32 IS - 1 AU - PAOLO BORGHETTI AU - MARCO LORENZO BONĂ™ AU - ELISA ROCA AU - SARA PEDRETTI AU - EMILIANO SALAH AU - ANNA BAIGUINI AU - DIANA GRECO AU - LUCA TRIGGIANI AU - MARTA MADDALO AU - NICCOLĂ’ GIAJ LEVRA AU - FILIPPO ALONGI AU - STEFANO MARIA MAGRINI AU - MICHELA BUGLIONE Y1 - 2018/01/01 UR - http://iv.iiarjournals.org/content/32/1/159.abstract N2 - Aim: To investigate the role of conventional radiotherapy (RT) and stereotactic body radiotherapy (SBRT) in patients with epidermal growth factor (EGFR)-mutant or anaplastic lymphoma kinase (ALK) rearrangement-positive metastatic non-small cell lung cancer (NSCLC). Patients and Methods: Fifty patients with EGFR-mutated or ALK rearrangement-positive NSCLC were treated at our Institution. Radiotherapy was delivered before, after or concomitantly with tyrosine kinase inhibitors (TKIs). Acute toxicities and overall survival (OS) were assessed. Results: Radiotherapy was performed within 30 days before TKI, concomitantly with TKI and within 30 days after TKI in eight (16%), 33 (66%) and 9 (18%) cases, respectively. The median duration of TKI therapy in the whole series was 11.9 months. The median OS was 19.3 months and 1- and 2-year OS was 71.5% and 36.5%, respectively. The group treated with SBRT had a significant benefit in terms of OS (p=0.043). Only two grade 3 toxicities were reported. Conclusion: RT concomitantly or close to TKI administration in stage IV NSCLC was shown to be feasible and safe. Intriguing data on OS were also reported. ER -